BioSpace

AbbVie wins FDA approval for Parkinson’s drug from $8.7B Cerevel takeover

In the Phase 3 TEMPO program, AbbVie’s Juvmo elicited significant improvements in motor symptoms and prolonged periods with good symptom control.

作者 BioSpace

1 分钟阅读
AbbVie wins FDA approval for Parkinson’s drug from $8.7B Cerevel takeover
AbbVie wins FDA approval for Parkinson’s drug from $8.7B Cerevel takeover

有活动行业的新闻要分享吗?

提交新闻稿或信息,触达数千名活动行业专业人士。

联系我们→

更多Health Tech相关内容

相关洞察